Fusion Pharmaceuticals Inc. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Fusion Pharmaceuticals Inc. reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$33.67 million for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-07.
Discontinued › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2024-05-07
- Fusion Pharmaceuticals Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2024-03-31 was -$33.67M.
- Fusion Pharmaceuticals Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2023-12-31 was -$28.18M.
- Fusion Pharmaceuticals Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2023-09-30 was -$17.25M.
- Fusion Pharmaceuticals Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2023-06-30 was -$25.18M.
- Fusion Pharmaceuticals Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2023 was -$94.90M.
- Fusion Pharmaceuticals Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2022 was -$87.61M.
- Fusion Pharmaceuticals Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2021 was -$81.05M.
- Fusion Pharmaceuticals Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2020 was -$78.33M.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2024-03-31 | -$33.67M 10-Q · filed 2024-05-07 | -$61.85M derived: sum of 2 quarters · filed 2024-05-07 | -$79.10M derived: sum of 3 quarters · filed 2024-05-07 | -$104.28M derived: sum of 4 quarters · filed 2024-05-07 |
| 2023-12-31 | -$28.18M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | -$45.43M derived: sum of 2 quarters · filed 2024-03-20 | -$70.61M derived: sum of 3 quarters · filed 2024-03-20 | -$94.90M 10-K · filed 2024-03-20 |
| 2023-09-30 | -$17.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$42.43M derived: sum of 2 quarters · filed 2023-11-07 | -$66.72M 10-Q · filed 2023-11-07 | -$91.33M derived: sum of 4 quarters · filed 2024-05-07 |
| 2023-06-30 | -$25.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$49.47M 10-Q · filed 2023-08-08 | -$74.08M derived: sum of 3 quarters · filed 2024-05-07 | -$98.10M derived: sum of 4 quarters · filed 2024-05-07 |
| 2023-03-31 | -$24.29M 10-Q · filed 2024-05-07 | -$48.91M derived: sum of 2 quarters · filed 2024-05-07 | -$72.92M derived: sum of 3 quarters · filed 2024-05-07 | -$91.99M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | -$24.62M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | -$48.63M derived: sum of 2 quarters · filed 2024-03-20 | -$67.70M derived: sum of 3 quarters · filed 2024-03-20 | -$87.61M 10-K · filed 2024-03-20 |
| 2022-09-30 | -$24.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$43.09M derived: sum of 2 quarters · filed 2023-11-07 | -$62.99M 10-Q · filed 2023-11-07 | -$80.23M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$19.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$38.98M 10-Q · filed 2023-08-08 | -$56.22M derived: sum of 3 quarters · filed 2023-08-08 | -$75.65M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$19.91M 10-Q · filed 2023-05-11 | -$37.15M derived: sum of 2 quarters · filed 2023-05-11 | -$56.57M derived: sum of 3 quarters · filed 2023-05-11 | -$83.43M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$17.24M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | -$36.66M derived: sum of 2 quarters · filed 2023-03-16 | -$63.52M derived: sum of 3 quarters · filed 2023-03-16 | -$81.05M 10-K · filed 2023-03-16 |
| 2021-09-30 | -$19.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$46.28M derived: sum of 2 quarters · filed 2022-11-08 | -$63.81M 10-Q · filed 2022-11-08 | -$77.20M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | -$26.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$44.38M 10-Q · filed 2022-08-09 | -$57.77M derived: sum of 3 quarters · filed 2022-08-09 | -$67.76M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | -$17.53M 10-Q · filed 2022-05-10 | -$30.91M derived: sum of 2 quarters · filed 2022-05-10 | -$40.91M derived: sum of 3 quarters · filed 2022-05-10 | -$85.64M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | -$13.38M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | -$23.38M derived: sum of 2 quarters · filed 2022-03-17 | -$68.11M derived: sum of 3 quarters · filed 2022-03-17 | -$78.33M 10-K · filed 2022-03-17 |
| 2020-09-30 | -$9.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | -$54.73M derived: sum of 2 quarters · filed 2021-11-09 | -$64.95M 10-Q · filed 2021-11-09 | -$73.15M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | -$44.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | -$54.95M 10-Q · filed 2021-08-10 | -$63.16M derived: sum of 3 quarters · filed 2021-08-10 | -$63.76M derived: sum of 4 quarters · filed 2021-08-10 |
| 2020-03-31 | -$10.22M 10-Q · filed 2021-05-11 | -$18.43M derived: sum of 2 quarters · filed 2021-05-11 | -$19.02M derived: sum of 3 quarters · filed 2021-05-11 | |
| 2019-12-31 | -$8.21M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | -$8.80M derived: sum of 2 quarters · filed 2021-03-25 | -$16.19M 10-K · filed 2021-03-25 | |
| 2019-09-30 | -$594.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | -$7.98M 10-Q · filed 2020-11-10 | ||
| 2019-06-30 | -$7.39M 10-Q · filed 2020-08-11 |